Skip to content
10-K

Annual Report

AXIM BIOTECHNOLOGIES, INC. AXIM

0001096906-24-000864

← back to feed
Filed
Apr 16, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Apr 13, 2024 278.43M sh
Capex FY 2023 · Dec 31, 2023 $0
Capex FY 2023 · Dec 31, 2022 $8.71K
Operating Cash Flow FY 2023 · Dec 31, 2023 −$1.03M
Operating Cash Flow FY 2023 · Dec 31, 2022 −$2.04M
Stockholders Equity FY 2023 · Dec 31, 2023 −$7.66M
Stockholders Equity FY 2023 · Dec 31, 2022 −$4.83M
Current Liabilities FY 2023 · Dec 31, 2023 $5.98M
Current Liabilities FY 2023 · Dec 31, 2022 $3.39M
Total Liabilities FY 2023 · Dec 31, 2023 $11.78M
Total Liabilities FY 2023 · Dec 31, 2022 $9.04M
Current Assets FY 2023 · Dec 31, 2023 $156.46K
Current Assets FY 2023 · Dec 31, 2022 $103.98K
Total Assets FY 2023 · Dec 31, 2023 $4.12M
Total Assets FY 2023 · Dec 31, 2022 $4.21M
Eps Diluted FY 2023 · Dec 31, 2023 −$0.04
Eps Diluted restated FY 2023 · Dec 31, 2022 −$0.04
Eps Basic FY 2023 · Dec 31, 2023 −$0.04
Eps Basic restated FY 2023 · Dec 31, 2022 −$0.04
Sga Expense FY 2023 · Dec 31, 2023 $2.24M
Sga Expense FY 2023 · Dec 31, 2022 $4.08M
Rd Expense FY 2023 · Dec 31, 2023 $125.5K
Rd Expense FY 2023 · Dec 31, 2022 $153.7K
Net Income FY 2023 · Dec 31, 2023 −$8.06M
Net Income FY 2023 · Dec 31, 2022 −$6.24M
Operating Income FY 2023 · Dec 31, 2023 −$2.75M
Operating Income FY 2023 · Dec 31, 2022 −$4.65M
Revenue FY 2023 · Dec 31, 2023 $39.52K
Revenue FY 2023 · Dec 31, 2022 $8.88K